Century Therapeutics, Inc. appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors.
Dr. Lee and Dr. Murphy bring extensive experience in biotechnology and life science investment.
The appointments aim to strengthen Century's leadership in developing innovative cell therapies for autoimmune diseases and cancer.
Appointment of Dr. Han Lee and Dr. Martin Murphy
Dr. Lee will serve on the Audit and Compensation Committees, while Dr. Murphy will serve on the Compensation and Nominating Committees.
Experience and Expertise
Dr. Lee has a background in capital formation and corporate development. Dr. Murphy's expertise lies in life science investment and company creation.
Pipeline Advancement
The appointments aim to advance Century's lead pipeline candidates, including CNTY-813 for type 1 diabetes, towards clinical trials.
- The addition of Dr. Lee and Dr. Murphy is expected to enhance Century's strategic oversight and value delivery to patients and stakeholders.
- Their combined expertise in capital formation, corporate development, and life science investment aligns with Century's focus on differentiated cell therapy programs.
Century Therapeutics' strategic appointments signal a pivotal moment for the company's growth and development in the biotechnology sector.